Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Antineutrophil properties of natural gingerols in models of lupus
Ramadan A. Ali, … , Duxin Sun, Jason S. Knight
Ramadan A. Ali, … , Duxin Sun, Jason S. Knight
Published December 29, 2020
Citation Information: JCI Insight. 2021;6(3):e138385. https://doi.org/10.1172/jci.insight.138385.
View: Text | PDF
Research Article Inflammation

Antineutrophil properties of natural gingerols in models of lupus

  • Text
  • PDF
Abstract

Ginger is known to have antiinflammatory and antioxidative effects and has traditionally been used as an herbal supplement in the treatment of various chronic diseases. Here, we report antineutrophil properties of 6-gingerol, the most abundant bioactive compound of ginger root, in models of lupus and antiphospholipid syndrome (APS). Specifically, we demonstrate that 6-gingerol attenuates neutrophil extracellular trap (NET) release in response to lupus- and APS-relevant stimuli through a mechanism that is at least partially dependent on inhibition of phosphodiesterases. At the same time, administration of 6-gingerol to mice reduces NET release in various models of lupus and APS, while also improving other disease-relevant endpoints, such as autoantibody formation and large-vein thrombosis. In summary, this study is the first to our knowledge to demonstrate a protective role for ginger-derived compounds in the context of lupus. Importantly, it provides a potential mechanism for these effects via phosphodiesterase inhibition and attenuation of neutrophil hyperactivity.

Authors

Ramadan A. Ali, Alex A. Gandhi, Lipeng Dai, Julia Weiner, Shanea K. Estes, Srilakshmi Yalavarthi, Kelsey Gockman, Duxin Sun, Jason S. Knight

×

Figure 5

Efficacy of 6-gingerol treatment after development of lupus phenotype in a lupus mouse model.

Options: View larger image (or click on image) Download as PowerPoint
Efficacy of 6-gingerol treatment after development of lupus phenotype in...
BALB/c mice were treated topically with TLR7 agonist (R848) or vehicle DMSO for 6 weeks (3 times per week). Starting at week 4 of treatment, some mice were additionally injected (i.p.) with 20 mg/kg 6-gingerol (3 times per week). Schematic of the TLR7 agonist–induced (R848) lupus model by week 4 followed by 6-gingerol treatment (A). NET levels in serum were assessed before and after 6-gingerol treatment by measuring MPO-DNA complexes (B). Anti–double-stranded DNA (anti-dsDNA) (C), anti–β-2 glycoprotein I (β2GPI) IgG (D), and total IgG (E) levels in serum were assessed by ELISA before and after 6-gingerol treatment. Mean is presented as a horizontal line; *P < 0.05, **P < 0.01, ***P < 0.001 by paired t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts